<DOC>
	<DOC>NCT02251613</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese patients (20 years of age or older) with a history of allergic conjunctivitis to Japanese Cedar Pollen. Patients will be randomly assigned to receive Olopatadine HCl ophthalmic solution, 0.1% in one eye and Epinastine HCl ophthalmic solution, 0.05% in the fellow eye, after which a conjunctival allergy challenge (CAC) with Japanese cedar pollen will be performed.</brief_summary>
	<brief_title>Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Epinastine</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<criteria>Be Japanese and live in Japan; History of allergic conjunctivitis; Positive skin test reaction to Japanese cedar at Visit 1; Positive bilateral CAC reaction to the allergen at Visit 1 and Visit 2; Able and willing to avoid all disallowed medications during the specified period; Able to discontinue wearing contact lenses during the specified period; Sign Informed Consent; Other protocoldefined inclusion criteria may apply. History of hypersensitivity to the study drug or compounds; Any ocular condition that, in the opinion of the investigator, could affect the patient's safety; Ocular surgical intervention within 3 months or refractive surgery within 6 months prior to the start of the study; Presence of active ocular infection; Use of disallowed medications as specified in the protocol; Pregnant, nursing, or planning to become pregnant during the study; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>